A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase by unknown
A Cellular Binding Site for the Mr 55,000 Form 
of the Human Plasminogen Activator, Urokinase 
JEAN-DOMINIQUE  VASSALLI, DANIEL  BACCINO,  and  DOMINIQUE  BELIN* 
Institute of Histology and Embryology and "Department of Pathology, University of Geneva, Geneva 4, 
Switzerland 
ABSTRACT  The  secretion  of  plasminogen  activators  has  been  implicated  in  the  controlled 
extracellular  proteolysis  that accompanies  cell  migration  and  tissue  remodeling.  We  found 
that the human plasminogen activator urokinase (Uk) (Mr 55,000 form) binds rapidly, specifi- 
cally, and with  high affinity  to fresh  human  blood  monocytes  and to cells  of the  monocyte 
line U937.  Upon binding,  Mr 55,000 Uk was observed  to confer high plasminogen  activator 
activity to the cells.  Binding of the enzyme did not require a functional  catalytic site (located 
on the B chain of the protein) but did require the noncatalytic A chain of Mr 55,000 Uk, since 
P/r 33,000 Uk did not bind. These results demonstrate the presence of a membrane receptor 
for Uk on monocytes and show a hitherto  unknown function  for the A chain of Uk: binding 
of secreted enzyme to its receptor results in Uk acting as a membrane protease.  This localizes 
plasminogen activation  near the cell surface,  an optimal site to facilitate cell migration. 
Various physiological and pathological processes, e.g.,  orga- 
nogenesis during embryonic development, invasive and met- 
astatic  spreading  of malignant  tumors,  and  inflammatory 
reactions, require that certain cell types transgress the normal 
anatomical boundaries of tissues and migrate in and out of 
different body compartments. To allow such cellular migra- 
tions, mechanisms that provide for the focal degradation of 
components of the  extracellular  matrix  must  be available. 
Although  the  enzymatic basis  for such  degradation  is  not 
completely understood,  several lines  of evidence have sug- 
gested that extracellular proteolysis catalyzed by the secretion 
of plasminogen activators may play an important part in the 
degradative events necessary for migration of cells in tissues 
(24). 
The plasminogen activator urokinase (Uk),~ originally iden- 
tified in human urine as an activator of the fibrinolytic system 
(27),  is  a  serine  protease  of tryptic  specificity; it  converts 
plasminogen, a zymogen, into plasmin, a neutral protease of 
broad specificity. Active human Uk consists of two polypep- 
tide chains linked by a disulfide bond, and exists in a  high 
molecular weight (Mr  55,000)  and  a  low molecular weight 
(Mr  33,000)  form; the latter is a  proteolytic product of Mr 
55,000  Uk  lacking most of the  A  chain  but  retaining the 
Abbreviations used in this paper:  AT-BSA, acid-treated BSA; DFP, 
diisopropylfluorophosphate;  EGF, epidermal growth factor; FBS, fetal 
bovine serum: TA, tissue activator: Uk, urokinase. 
active site-containing B chain (10).  It is now well established 
that  a  variety of cell  types synthesize and  secrete Uk-type 
plasminogen activators (9); these include cells endowed with 
migratory and invasive properties, such as monocytes-mac- 
rophages (34),  polymorphonuclear leukocytes (37),  and im- 
planting trophoblast (30),  and cells derived from malignant 
tumors (19). 
We describe here the specific binding of Mr 55,000 Uk to 
the surface of U937  cells,  a  monocyte-like human cell  line 
(31), and to freshly prepared human peripheral blood mono- 
cytes. This interaction provides a  means by which Uk-pro- 
ducing cells  can express both a  secreted and a  membrane- 
associated form of the enzyme. Enzymatic activity of mem- 
brane-bound Uk is localized to the vicinity of the cell surface, 
where it can catalyze the focal lysis of extracellular substrates, 
and may thereby facilitate monocyte migration. 
MATERIALS  AND  METHODS 
Cell Culture:  U937 cells were grown in RPMI  1640 (Gibco Laborato- 
ties,  Grand  Island,  NY) supplemented  with  5%  fetal bovine  serum (FBS) 
(Gibco Laboratories), and cultures were split V3 every 4 d. 
Monocyte-entiched  cultures  were prepared  from  FicolI-Hypaque-purified 
human peripheral blood mononuclear cells (3). Mononuclear cells were plated 
in fibrinogen-coated (10 #g/cm  2) Nunc (Bio AG, Basel, Switzerland) 24-well 
tissue culture plates (3 x  106 cells in 1 ml RPMI  1640 with  10% FBS that had 
been heated  for 30 min at  56"C [HI-FBS]). 5 h later the wells were washed 
twice vigorously with RPMI  1640, and the cultures were incubated further for 
16 h in RPMI  1640 with 10% HI-FBS. 
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twice in  RPMI  1640, and resuspended  at  1 x  106 cells/ml  in RPMI  1640 
containing  1 mg/ml acid-treated  (17) BSA (A-7638, Sigma Chemical  Co, St 
Louis, MO) (AT-BSA). Aliquots of  0.3 ml were distributed to Falcon No. 2058 
tubes (Falcon  Labware, Div., of Becton, Dickinson  & Co., Oxnard,  CA) and 
incubated as indicated. At the end of the incubation,  the cultures were centri- 
fuged (500 g, 5 min, 4"C) and the medium was collected and mixed with an 
equal volume of 2 x electrophoresis sample buffer (0.1 M Tris-Cl, pH 6.8, with 
2% SDS and 20% glycerol). For the experiment  of Fig.  I, cells were washed 
three times with PBS +  1 mg/ml AT-BSA, resuspended in 0.15 ml PBS + AT- 
BSA, and mixed with an equal volume of 2 x  electrophoresis sample buffer. 
For all other experiments, cells were resuspended in PBS + 3 mg/ml AT-BSA, 
spun through a layer of 5% sucrose and 2.5 mg/ml AT-BSA in PBS (800 g, 5 
min, 4"C), and finally lysed in 50 gl 1 x electrophoresis sample buffer. 
The  monocyte  cultures  were  washed  four times  with  RPMI  1640 and 
incubated with J251-Uk in RPMI  1640 +  3 mg/ml AT-BSA. After incubation, 
the cultures were washed five times with PBS +  3 mg/ml AT-BSA, and the 
cells were lysed in I ml I M NaOH. 
Radioactivity  in the media  and cell lysates was determined  in a Beckman 
Gamma 310 counter (Beckman Instruments, Inc., Palo Alto, CA). 
Gel  Electrophoresis and Autoradiography:  Samples  (15  ul) 
were applied to 9% polyacrylamide slab gels in the presence of SDS (15, 34); 
after electrophoresis the gels were fixed and stained (0.2% Coomassie Blue in 
30% methanol  and 7.5% acetic acid), destained, and exposed to Kodak XAR- 
5 film for 16 h at -80"C using DuPont Cronex Par-Speed intensifying screens 
(E.I.  DuPont  de  Nemours &  Co.,  Newton,  CT).  Molecular  weights were 
calculated  from  the position  of markers  (Pharmacia,  Uppsala,  Sweden; low 
molecular weight calibration kit) in the stained gels. 
Immunofluorescence:  Cultured  monocytes-macrophages  were 
washed twice with PBS +  1 mg/ml BSA, incubated  for 30 rain at 20*(? in the 
presence or absence of M, 55,000 Uk (1 x  10  -~ M in PBS + BSA) or/14",  33,000 
Uk (2 x  10  -8 M), washed three times with PBS + BSA, incubated  for 15 rain 
at 4"C in presence of rabbit anti-human Uk IgG or irrelevant lgG (0.1 mg/ml 
in PBS + BSA), washed three times with PBS + BSA, incubated  15 rain at 4"C 
in the presence of fluorescein-labeled sheep immunoglobulins  anti-rabbit  IgG 
(heavy and light chains) (lnstitut  Pasteur Production,  Paris, France) (10 ug/ml 
in PBS), and finally washed four times with PBS +  BSA. Photographs  were 
taken  on a  Zeiss Photomicroscope  2  with  RS3  epifluorescence  optics onto 
Kodak Ektachrome 400 film. 
Plasminogen Activator Plaque Assay:  U937 cellswereincubated 
with Uk, washed by centrifugation  through sucrose as described above under 
binding studies, resuspended  in  easein-agar-plasminogen  medium (36), and 
plated in Falcon 35-mm tissue culture dishes. 
Ficoll-Hypaque-purified  mononuclear cells were plated  in Falcon  35-mm 
tissue culture dishes (1.3 x  l0  s cells in 1.5 ml RPMI  1640 with  10% HI-FBS). 
After 24 h of incubation,  the cultures were washed four times with PBS, kept 
for 30 min at 37"C in RPMI  1640 +  1 mg/ml AT-BSA with or without added 
Uk, washed again three times with PBS, and overlayed with the casein-agar- 
plasminogen medium. 
Photographs were taken  using dark-ground  illumination.  The dark plaques 
represent zones of  casein lysis surrounding  cells or groups of cells; lysis was not 
observed when plasminogen was omitted  from the assay mixtures. 
Preparation of Reagents:  M, 55,000  Uk (high molecular  weight) 
was obtained from the Green Cross Corporation (Osaka, Japan) and '251-labeled 
using lodogen  (Pierce Chemical  Co,  Rockford,  IL) and  Na-t251 (Amersham 
Ltd., Amersham,  England) as described (1), except that spun Sephadex G-50 
(Pharmacia,  Uppsala, Sweden) columns (18) were used to separate the protein 
from unreacted  ~251. Mr 55,000  J251-Uk had a specific activity of-1.9 x  10  7 
cpm//~g and was at least 80% enzymatically active (8). Mr 33,000 Uk was the 
generous gift of Serono (Denens, Switzerland), and was ~Z~l-labeled as described 
for M, 55,000 Uk; Mr 33,000 Jz~i-Uk had a specific activity of ~1 x  107 cpm/ 
~g, showed a single band of radioactivity with an apparent  Mr of 33,000 after 
SDS PAGE, and was at least 80% enzymatically active. 
3'/,  55,000 and  33,000 unlabeled  and  ~2~l-labeled Uk  were reacted  with 
diisopropylfluorophosphate  (DFP, Merck AG, Darmstadt,  Federal Republic of 
Germany) in 0.5  M NaPO4, pH 7.4, by two additions  of 10 mM DFP, for a 
total of I h at 20"C; enzymatic assays (8) of DFP-Uks showed that the enzymes 
had been inactivated by >95%. 
Plasminogen was purified from human plasma by lysine-Sepharose (Phar- 
macia) affinity chromatography (6). Plasmin was prepared as described (8), and 
reacted with DFP as described for Uk. Murine epidermal growth factor (EGF) 
(culture grade) was from Collaborative Research Inc., (Lexington, MA), bovine 
insulin and human thrombin from Sigma Chemical  Co., and human Factor 
Xa  from  Boehringer  GmbH  (Mannheim,  Federal  Republic  of Germany). 
Human tissue activator (TA), purified from culture medium of HeLa cells, was 
the kind gift of Dr. W.-D. Schleuning and was I~I-labeled as described for Uk; 
1251-TA had a specific activity of ~4 x  10  ~ cpm/#g, showed a predominant M, 
75,000 radioactive  band after SDS PAGE, and in contrast  to the  unlabeled 
enzyme, was catalytically inactive (8). Rabbit antibodies to human urinary Uk 
were also generously provided by Dr W.-D. Schleuning (39); IgG were prepared 
by Protein A-Sepharose affinity chromatography  (l 2). 
RESULTS 
The plasminogen activator secreted by human  monocytes- 
macrophages and  U937  cells  is electrophoretically and im- 
munologically identical to Mr 55,000 Uk (34). To investigate 
the fate of  Uk after secretion, we added ~2SI-labeled  M~ 55,000 
enzyme to U937 cells in culture. Cells and media were col- 
lected  after  30  min  of incubation  at  37"C,  and  the  cell- 
associated  radioactivity was  determined; the  samples  were 
also subjected to SDS PAGE under nonreducing conditions, 
and  the  gel  was  analyzed by autoradiography (Fig.  1).  A 
substantial fraction (13.2  __. 0.1%) of the total radioactivity 
added to the cultures was associated with the cells and mi- 
grated with an apparent Mr of 55,000 (lane 2); in the presence 
of a  60-fold excess of unlabeled Mr 55,000 Uk, only 1.1  + 
0.2% of the added radioactivity was cell associated (lane 4). 
Radioactivity remaining in  the  medium was  quantitatively 
recovered as two major bands (lane I): an Mr 55,000 band, 
corresponding to the added 125I-Uk, and an M~ 94,000 band, 
corresponding to a covalent complex formed between Uk and 
a  plasminogen activator-specific inhibitor secreted by U937 
cells (34); this complex was not observed in the presence of 
excess  unlabeled  Uk  (lane  3),  the  secreted inhibitor being 
saturated under these conditions. Cellular binding of ~25I-Uk 
showed only little temperature dependence: after 60 min of 
FIGUR~  1  Binding of Mr 55,000 1251-Uk to U937 cells. Lanes 1 and 
3,  media;  lanes  2  and  4,  cells.  Incubation  (30  min,  37°C)  of M, 
55,000 12sI-Uk (3 x  10  -1° M) with  U937 cells was performed in the 
absence (lanes  I  and  2) or presence (lanes 3  and 4) of unlabeled 
M, 55,000 Uk (1.8 x  10  -8 M). Culture media and cell lysates were 
prepared and subjected to SDS PAGE followed by autoradiography. 
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vated M~ 55,000  12sl-Uk to  U937 
cells.  Duplicate cultures (I,  2) of 
U937  cells  were  incubated  (90 
min, 20°C) in the presence of (A) 
Mr 55,000  12Sl-Uk (5  x  10  -1° M); 
(B)  same as A  plus  unlabeled M, 
55,000 Uk (1.6 x  10  -8 M); (C)  M~ 
55,000  DFP-~2sI-Uk  (3.5  x  10  -l° 
M);  or  (D)  same as C  plus  unla- 
beled M~  55,000  Uk  (1.6  x  10  -8 
M).  Both ~2sl-Uk and DFP-~ZsI-Uk 
had the same specific activity (1.9 
x  10  e cpm/ug).  Cell  lysates were 
prepared  and  subjected  to  SDS 
PAGE  followed  by  autoradiogra- 
phy.  Cell-bound  usI-Uk  repre- 
sented 9.7 and  10.4% of the total 
radioactivity  in  cultures  A1  and 
A2,  0.2  and 0.2'/o in  B1  and  B2, 
11.4 and 11.7% in C1 and C2, and 
0.2 and 0.1% in D1  and D2. 
incubation,  15.5 +_. 0.6% of the added  t25I-Uk was cell asso- 
ciated  at  37"C,  and  12.3  ___  0.3%  at  0*C, indicating  that 
endocytosis of the enzyme was probably not involved. These 
results suggested the existence of a saturable binding site for 
free 125I-Uk on the surface of U937 cells, and further experi- 
ments were carried out to characterize this interaction. 
To investigate the  contribution  of the enzyme's catalytic 
site on the cellular binding of Uk, we reacted Mr 55,000 ~25I- 
Uk with DFP, an inhibitor ofserine esterases that irreversibly 
phosphorylates their active site.  DFP-inactivated Mr 55,000 
~25I-Uk  bound to U937 cells as effectively  as the active enzyme 
(Fig. 2, lanes in A and C), and this binding was also completely 
prevented in the presence of an excess of unlabeled Mr 55,000 
Uk (Fig.  2, lanes in B and D), or Mr 55,000 DFP-Uk (Table 
I). We concluded that enzymatic activity was not necessary 
for cellular binding  of Uk,  and  that the  catalytic site  was 
probably not involved in this binding. Since DFP-~25I-Uk does 
not form a  covalent complex with the U937-produced plas- 
minogen activator-specific inhibitor, ~25I-Uk  binding to U937 
cells did not appear to be a consequence of covalent complex 
formation with this ligand. Nevertheless, to avoid the influ- 
ence of possible secondary interactions between bound  Uk 
and this ligand (such interactions being presumably respon- 
sible for the Mr 94,000  radioactive band associated with the 
cells after longer incubations with Mr 55,000 12sI-Uk [compare 
Fig.  1, lane 2,  and the lanes in Fig.  2A]), we chose to carry 
out the following experiments using DFP-inactivated ~25I-Uk. 
Cellular binding of M~ 55,000  DFP-t25I-Uk was fast,  half- 
maximal specific binding being achieved in <7 min at 20"C 
(Fig.  3A). We also determined the amount of enzyme bound 
in  the  presence  of increasing concentrations  of Mr  55,000 
DFP-t25I-Uk (Fig.  3B).  By Scatchard analysis of these data 
(Fig. 3 C), we estimated the number of binding sites per U937 
cell  at approximately 60,000;  the Kd of the  interaction was 
calculated to be on the order of 4 x  10  -~° M. 
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TABLE  I 
Specificity of the Binding of Mr 55,000 Uk to U937 Cells 
No competi- 
tor  DFP-Uks5  DFP-Uk33  TA 
DFP-1251-Ukss  5.2 ±  0.2  0.4 +  0.1  4.8 +  0.7  4.0 ±  0.4 
DFP?ZSI-Uk33  0.1  ±  0  0.1  ±  0  0.2 ±  0.1  NT 
~2SI-TA  0.9 +  0.1  0.8 ±  0.1  NT  0.7 ±  0.1 
U937 cells were cultured  for 90 min at 4°C in the presence of the ligands 
and competitors  as indicated.  After incubation  the cells were washed and 
lhe cell-associated radioactivity  {percent of total) was determined  Jresults  are 
expressed as the mean ~  SEM of two determinations).  Ligands were added 
at the following concentrations:  Mr 55,000  DFp-I~SI-Uk, 5~4 x  10  -l° M; M, 
33,000 DFP-'2sbUk, 1.5 x  10  -9 M; 12SI-TA, 2.3 x  10  -'0 M. Competitors:  Mr 
55,000 DFP-Uk, 2 x  10  -8 M; Mr 33,000 DFP-Uk, 4.5 x  10  -8 M; TA, 1 x  10  -0 
M. NT, not tested. (Ukss and Uk33, Mr 55,000 and  33,000 Uk, respectively, 
here and in the following tables) 
UK is synthesized and secreted as a one-chain, Mr 55,000, 
zymogen (21, 38). Limited proteolysis by plasmin can convert 
this proUk into the two-chain, Mr 55,000, active enzyme (21, 
38), composed ofa 158 amino acid A chain and a 253 amino 
acid B chain, linked by a disulfide bond (l 1). This Uk form 
predominates in urine (8). An Mr 33,000 form is also found 
in urine and cell culture media; it is composed of an intact B 
chain and a "mini" A chain consisting of the C-terminal 21 
amino acids of the A chain (10,  29).  We have analyzed the 
binding of Mr 33,000 DFP-Uk to U937 cells (Table I): we did 
not detect any specific binding of the  ~zSI-labeled  protein; in 
addition, using a  nearly  100-fold  molar excess of Mr 33,000 
DFP-Uk,  we  found  no  inhibition  of binding of Mr  55,000 
DFP-~25I-Uk. These results indicate that Uk binding to U937 
cells is a property of the M~ 55,000 form of the enzyme. Since 
Mr 33,000 Uk differs from Mr 55,000 Uk only by the absence 
of most of the enzyme's A chain (10),  the cellular binding of 
Uk  requires  the  presence  of determinants  of the  intact  A 
chain. / 
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FIGURE  3  Binding of Mr 55,000  DFP-~2sI-Uk to  U937 cells.  (A)  U937 cells were cultured  at 20°C  for various periods of time  in 
the presence of M, 55,000  DFP-~2sI-Uk (6 x  10  -~° M), with  (O) or without  (x) the addition of unlabeled A4~ 55,000 DFP-Uk (1.4 x 
10  -8 M). After incubation the cells were washed, and cell-associated radioactivity was determined.  (B) U937 cells (2 x  106/ml, 0.3 
ml/culture)  were  incubated  for 90  min  at 20°C,  in the  presence of twofold  increasing concentrations  of Mr 55,000  DFP-~2sI-Uk 
(from 2.2  x  10  -~  M  to  1.4 ×  10  -9 M). After incubation  the cells were washed, and cell-associated  radioactivity was determined. 
Specifically  bound Uk was calculated  by subtracting the counts per minute bound in the presence of 1.6 x  10  -~ M  un[abeted M~ 
55,000  DFP-Uk.  (Nonspecific  binding  never exceeded  1% of total counts  per  minute  in the cultures,  and 8% of total counts  per 
minute  bound to the cells.) (C) Scatchard analysis of the data presented in B. 
The amino acid sequence of human Uk has recently been 
elucidated (1 l, 29). Two regions of the A  chain of Uk show 
homologies with other proteins: an N-terminal region (amino 
acids  13  to 43)  presents clusters of sequences that are also 
found in murine EGF and in bovine blood factor X, whereas 
residues 50 to 132 show 42% of identity with the fifth kringle 
of  human  plasminogen  (l 1),  and  48%  with  the  putative 
second kringle of human TA (23).  We determined whether 
other proteins with homologies to the A  chain of Uk might 
compete with Mr 55,000  t2sI-Uk  for cellular binding (Tables 
I  and  II): neither human  factor Xa,  murine EGF,  human 
plasminogen, DFP-plasmin,  nor human TA caused any de- 
crease in  the amount of Mr  55,000  DFP-J2~I-Uk  bound to 
U937  cells.  Furthermore,  we  did  not  detect  any  specific 
binding of ~2~I-TA. Finally insulin, for which receptors have 
been described on monocytes (26) and U937  cells (25), and 
thrombin, recently reported to bind to (7) and be a chemo- 
tactic agent for human monocytes (2), were without effect on 
Mr 55,000 12sI-Uk  binding. These results thus suggest that the 
U937 cellular binding site may be specific for Mr 55,000 Uk. 
Specific  cellular  binding  of Mr  55,000  ~25I-Uk was  also 
observed  when  monocyte-enriched cultures  prepared  from 
human venous blood mononuclear cells were incubated with 
DFP-inactivated enzyme (Table III); Mr 33,000 DFP-Uk did 
not bind to these cells (data not shown), nor did it prevent 
the binding  of Mr  55,000  Uk.  Binding  is therefore not re- 
stricted to the monocyte-like U937 cell line. To visualize Uk 
bound  to  cultured  monocytes,  we  used  antibodies  raised 
against the human enzyme. Indirect immunofluorescence did 
not  reveal  specific  staining  of  untreated  cells  (Fig.  4A), 
whereas 70% of cells that had been exposed to Mr 55,000 Uk 
were positive (Fig. 4B); binding of Mr 55,000 Uk can thus be 
demonstrated on most cultured monocytes-macrophages, and 
it  is  therefore  not  the  property  of a  subpopulation  or  a 
contaminant in our cultures. 
Since the cellular binding of Uk does not require a func- 
tional catalytic site,  the bound enzyme may be active, and 
Uk secretion followed by binding to a  high-affinity cellular 
site could  result in  Uk functioning in  part as a  cell-bound 
TABLE  II 
Specificity of the Binding of Mr 55,000 Uk to U937 Cells 
Inhibition 
Added component  Final concentration  of binding 
M  % 
Ukss  2.5 X  10  -a  93 +_ 1 
DFP-Ukss  2.5 X  10  -a  92 +  2 
Plasminogen  1 x  10  -7  -6  _  5 
DFP-plasmin  1 x  10  -7  -8  _  3 
Factor Xa  4  x  10  -8  11 4- 1 
Thrombin  4  x  10  -a  8 4-  1 
EGF  1.7 x  10  -6  -25  _+  13 
Insulin  1.7 x  10  -6  8 4- 2 
The experimental protocol is the same as for Table I. Percent inhibition was 
(alculated relative to controls containing Mr 55,000 DFP-I:SI-Uk  (3 x  10  -'° 
M) added to the cells in the absence of competitors; under these conditions 
bound counts per minute represented 11.9 _+ 0.8% of total counts per minute 
added to the cultures. 
TABLE III 
Binding of M, 55,000 Uk to Human Monocytes 
No competitor  DFP-Ukss  DFP-Uk33 
Monocytes  5.2 4- 0.5  0.5 4- 0  5.2 4- 0.2 
Control  plates  0.4 4- 0.1  0.5 4- 0  0.4 4- 0.1 
Monocytes were cultured for 30 min at 20°C in presence of the ligand (M, 
55,000 DFP-USI-Uk,  5.8 x  10  -~° M) and competitors (M, 55,000 DFP-Uk, 1.7 
x  10  -8 M; Mr 33,000 DFP-Uk, 2.8 X  10  -8 M) as indicated. After incubation 
the cells were washed, and the cell-associated radioactivity (percent of total) 
was determined. Control plates were prepared and treated in parallel,  except 
that mononuclear cells were not added. 
enzyme. To examine the validity of this hypothesis, we incu- 
bated U937  cells and monocytes with M, 55,000  or 33,000 
Uk, washed the cells, and analyzed their plasminogen activa- 
tor activity by the casein-agar overlay procedure (Fig. 5). After 
incubation, proteolytic plaques surrounded a few of the U937 
cells that had not been exposed to exogenous Uk (Fig.  5A); 
these were due to the cellular synthesis and secretion of Uk. 
U937 cells that had been exposed to Mr 55,000 Uk produced 
VASSALLI ET AL.  Cellular  Binding of M, 55,000 Urokinase  89 FIGURE  4  Immunofluorescence detection of Mr 55,000 Uk bound to cultured monocytes-macrophages. Cells were incubated in 
the absence (A)  or presence (B) of Mr 55,000  Uk (1  x  10  -~ M),  and  bound  Uk was visualized on  live, unfixed cells  by indirect 
immunofluorescence using rabbit antibodies directed  against human  Uk.  Controls included  cells  incubated with  Mr 33,000  Uk 
and (;ells  incubated with Mr 55,000 Uk followed by irrelevant IgG; fluorescence of control cultures was comparable to that of A. 
x  600. 
FIGURE  5  Plasminogen activator plaque assay of U937 cells and monocytes. Effect of exogenous Mr 55,000 Uk. U937 cells were 
incubated for 60 rain at 4°C, without (A) or with  (B) M, 55,000 Uk (1.1  x  10  -9 M) or lVlr 33,000 Uk (C) (1.8 x  10  -9 M). The cells 
were washed,  resuspended  in  casein-agar-plasminogen medium,  and  plated  in tissue culture  dishes.  Photographs were taken 
after 3 h of incubation of 37°C. Monocytes were incubated for 30 min at 37°C, without (A) or with (B) Mr 55,000 Uk (1.2 x  10  -9 
M) or (C) M, 33,000 Uk (2.4 x  10  -9 M). The cells were washed and ovedayed with casein-agar-plasminogen medium. Photographs 
were taken after 40 min of incubation at 37 °C. ×  1.6. 
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matic  activity  of the  exogenously added  Uk,  and  not  to 
increased Uk synthesis by treated cells,  since cycloheximide 
(5 ~g/ml) did not prevent the increase in plasminogen acti- 
vator activity after exposure to Mr 55,000 Uk, and since cells 
that had bound Mr 55,000 DFP-inactivated Uk did not pro- 
duce more plaques than did control cells (data not shown). 
Finally, addition of Mr 33,000 Uk did not increase the pro- 
teolytic activity of U937 cells (Fig.  5 C). Similar results were 
obtained with  human monocytes: no lysis  was observed in 
control cultures (Fig. 5A) or in cultures that had been exposed 
to Mr 33,000  Uk (Fig.  5 C), whereas Mr 55,000  Uk-treated 
cultures produced many proteolytic plaques (Fig. 5 B); phase- 
contrast  microscopy confirmed that the  zones of lysis  sur- 
rounded  monocytes-macrophages. We concluded  that  cell- 
bound Mr 55,000 Uk remains at least in part enzymatically 
active, and can thereby catalyze plasmin-mediated proteolysis 
around monocytes and U937 cells. 
DISCUSSION 
The cellular binding  of the  plasminogen  activator Uk  (Mr 
55,000  form) provides a  mechanism by which the enzyme 
can function not only as a secreted protease, diffusing away 
from its site of synthesis, but also in a membrane-associated 
form,  catalyzing  focalized  plasmin  formation  and  thereby 
high proteolytic activity in the close environment of the cell. 
Although the role of plasminogen activator in the biology of 
mononuclear  phagocytes  remains  a  matter  of conjecture, 
enzyme production is thought to be related to the migratory 
properties of these cells (35).  In this context, a  membrane- 
bound plasminogen activator is optimally located to generate 
proteolytic activity along the path of monocyte migration. In 
addition, membrane-bound Uk may be less susceptible to the 
protease inhibitors  present  in  the  extracellular fluid  (4,  5). 
Plasminogen activation has been postulated to be essential for 
the migratory and invasive properties of other Uk-producing 
cells,  such as implanting murine trophoblasts (30) or malig- 
nant cells (19, 22); similar Uk-binding sites may thus exist on 
the surface of these cells as well. 
Binding of Mr 55,000 Uk to human monocytes and U937 
cells may be related to the  fact that these  cells  themselves 
produce Uk (34). We propose that during or following secre- 
tion,  at  least  some  of the  (pro?)enzyme binds  to  the  cell 
surface. In this respect, it is of interest to note that murine 
macrophages, which synthesize a Uk-type enzyme (in prepa- 
ration), express a membrane-associated form of plasminogen 
activator (5,  16, 28).  The interaction described here suggests 
that this membrane-associated form of the enzyme is due to 
the binding of secreted Uk to a high-affinity cell membrane 
receptor, rather than to the synthesis and membrane insertion 
of a distinct species of plasminogen activator. It should also 
be recalled that Uk and proUk are present in human plasma 
(32,  39),  at a concentration (1-2 x  10-~°M) which is on the 
order of the/~ value determined in this paper for Mr 55,000 
Uk binding to U937 cells. One may thus speculate that cells 
can bind circulating enzyme, or enzyme produced by neigh- 
boring cells in the environment of a tissue. 
The Mr 33,000 form of Uk did not bind to the cells studied; 
it differs from Mr 55,000 Uk by the absence of the first 135 
amino acids of the  158 amino-acid A  chain.  This indicates 
that determinants of the A chain are necessary for binding to 
occur, although at this time it cannot be taken to imply that 
the A chain itself does bind to the cellular receptor. To further 
characterize the cellular binding of Mr 55,000 Uk, it will be 
of interest to evaluate the binding of proUk, and of various 
fragments derived from the A chain of the enzyme. In any 
event, the requirement for the presence of an intact A chain 
for cellular binding of Uk provides a novel function for this 
domain of the molecule. 
We did not detect any significant competition for binding 
of Mr 55,000 Uk by other proteins with homologies to the A 
chain  of the enzyme, nor by thrombin, suggesting that the 
binding site is specific for Uk. Binding of both thrombin and 
a  functional prothrombinase complex (consisting of factors 
Va and  Xa) to human  monocytes have also recently been 
described (7, 33). Fibrin formation as well as fibrinolysis can 
thus be catalyzed at or near the surface of monocytes-mac- 
rophages; membrane binding sites for these seemingly antag- 
onistic reactions appear to be different, and regulation of their 
expression may control the overall deposition and removal of 
fibrin around these cells,  in particular within inflammatory 
lesions. 
The cellular binding of Mr 55,000  Uk contrasts with the 
absence of interaction between the other human plasminogen 
activator, namely TA, and the cells studied in this work. We 
suggest that Mr 55,000 Uk is a form of plasminogen activator 
with an affinity for the cell surface, where it catalyzes plasmin 
formation in the close environment of the ceil,  in the same 
way that TA represents a form of plasminogen activator with 
an affinity for fibrin clots where it catalyzes a high plasmin- 
mediated thrombolytic activity (20).  The determinants that 
direct these specific extracellular localizations appear to reside 
in  the  A  chains  of both  enzymes.  The  recently described 
adsorption of TA to cultured fibroblasts (13) suggests that this 
form of plasminogen activator also can become cell associ- 
ated.  However, in  contrast with the cellular binding of Uk 
described here, binding of TA was due to the formation of an 
SDS-resistant  complex between  the  enzyme and  a  cellular 
ligand; furthermore, TA adsorption to fibroblasts was slow as 
compared with that of Uk to U937 ceils, and appeared to be 
involved in the clearance of the enzyme. 
Finally, the interaction of Uk with U937 cells and mono- 
cytes  could  be  considered  as  that  of a  hormone  with  its 
membrane receptor.  The region  within  the A  chain  of Mr 
55,000  Uk which  is homologous to murine  EGF has been 
described as a "growth factor domain" (11). Our studies show 
that EGF does not compete for the Uk binding site; neverthe- 
less, we intend to search for possible "trophic" effects of Mr 
55,000 Uk on monocytes and other cells. Increased levels of 
Uk have been observed in malignant tumors (19), and auto- 
crine effects (14) may be responsible for some aspects of the 
malignant phenotype. 
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